DENVER, Feb.  27, 2026  (GLOBE NEWSWIRE) -- Markets reward momentum and trends may sustain when execution follows headlines. Several companies are now moving beyond announcements and into operational validation,

ENSC

Follow-Through Leaders: Production Ramps, AI Alliances, Balance Sheet Strength

Ensysce Biosciences Initiates Strategic Review to Boost Shareholder Value

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 DENVER, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Markets reward momentum and trends may sustain when execution follows headlines. Several companies are now moving beyond announcements and into operational validation,
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 Ensysce Biosciences has launched a strategic review aimed at enhancing shareholder value through various potential avenues, including partnerships and licensing. This move could catalyze investment interest and boost stock performance, particularly for its innovative platforms.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Ensysce Biosciences reviewing strategic alternatives to enhance shareholder value.</li><li>Potential actions include partnerships, licensing, asset sales, or corporate combinations.</li><li>Management aims to unlock value from its abuse-deterrent and overdose-protection technologies.</li><li>Strategic reviews can provide optionality for clinical-stage biotech companies.</li><li>No timeline set for the outcome of the strategic review.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>Ensysce Biosciences (ENSC): Initiating a strategic review that may enhance shareholder value.</li></ul>
 </section>

 <section data-block="category">
 <h3>Corporate Developments</h3>
 This news fits under &#039;Corporate Developments&#039;, as it involves strategic decisions intended to improve the company&#039;s standing and valuation, a critical aspect for investors considering the potential future of ENSC&#039;s platforms.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>Strategic alternatives may attract positive investor sentiment and lift stock price.</li><li>Successful partnerships could enhance revenues and accelerate platform development.</li><li>Market perception of Ensysce&#039;s platforms&#039; value may shift during the review process.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>Ensysce initiated a strategic review on February 27, 2026.</li><li>The review includes potential partnerships and capital formation strategies.</li><li>Focus areas are the TAAP™ and MPAR® platforms.</li><li>Management emphasizes disciplined execution during this review.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Buy ENSC with a target horizon of 6-12 months for potential upside.
 </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link>DENVER, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Markets reward momentum and trends may sustain when execution follows headlines. Several companies are now moving beyond announcements and into operational validation, positioning themselves for potential continued follow-through. From biomaterials scale-up to enterprise AI deployment and disciplined capital allocation, these names are building narratives that extend beyond a single news cycle. Kraig Biocraft Laboratories: From Strategy to Scale Activity has accelerated at Kraig Biocraft Laboratories (OTCQB:<a class="ticker" href="https://www.benzinga.com/quote/KBLB">KBLB</a>) following confirmation that its 2026 production plan has officially transitioned from roadmap to execution. The company has moved bio-material into incubation, initiating its March production run and activating the first wave of its multi-ton spider silk scale-up initiative. Management framed the milestone clearly: "This is the moment where planning becomes production." The March run represents the first major deployment under the company's 2026 strategy, which targets sustained monthly production of recombinant spider silk cocoons at unprecedented commercial volumes. The vertically integrated model, spanning silkworm rearing through downstream processing, aims to reinforce supply chain control and commercial readiness. Layered on top of operational momentum, Kraig's recombinant spider silk technology was featured on the cover of the recently published, March 2026, issue of National Geographic. The feature highlighted the scalability of its genetically enhanced silkworm platform and included demonstrations showcasing tensile strength, including towing a car and suspending a person using a lightweight loop of thread. <img alt="KBLB National Geographic March 2026 Newsstand Cover Art" height="600" src="https://ml.globenewswire.com/Resource/Download/9733713a-33c0-43ba-82dc-adc50e9aa189/kblb-national-geographic-march-2026-newsstand-cover-art.jpg" width="413" data-dpi="300" data-caption="Kraig Biocraft Laboratories (OTCQB:<a class="ticker" href="https://www.benzinga.com/quote/KBLB">KBLB</a>) featured on Cover of March 2026 National Geographic" data-filename="KBLB National Geographic March 2026 Newsstand Cover Art.jpg"></img> Visibility plus execution is a powerful combination. With production cycles now underway and commercialization efforts expanding into apparel, medical, industrial, and defense applications, KBLB is transitioning from proof-of-concept to production-phase validation. Interested persons can order a copy of the magazine from National Geographic at <a href="https://www.globenewswire.com/Tracker?data=718RndY2rvQqs0n1oq4UqUZuv-_uwFBSp0qn99lqRFg1bOO2MeMbZ5mBpR0te4UsLOQtFf5NV2Ihb05-U82vo-7W5_XXsKAdEa20e9oNgsbfNk-HsI5SGsE307DO8smxO0ZYJJL0yxnsQ-bX8vH52stzTniuCNECCk1l6fUAMCdu-PySs7jmz7QNf1ZltxZeE3v8I-G790P6kwgIiII9bQ==" rel="nofollow" target="_blank">https://ngsingleissues.nationalgeographic.com/natgeo-march-2026</a>. You can purchase a digital copy of the article directly from National Geographic at <a href="https://www.globenewswire.com/Tracker?data=718RndY2rvQqs0n1oq4UqSCY0DZFX6a4-fKExUUfSFR4hM9UqkVfPuH_ZrnIcN8LR8E5RPGZAnVzEvzaxegjR6hWbyXK1pYMt9E-eL8UKTGdcbBSxvlrjfBq4nP3jHrP1l9oSJO6eZ0iM1M9uuYvx7iH_RndyK7VE6-oQRQ6P-KTNUpMEJwC_HfYRJM_PT29QtnHyRq9wGk3LTmYZ-RWbcdkUiTfIruJzV5wZZGPp4m1qhGhIzv0cJxTMuCJak4bLA9YJD_Te7rpBCQ1iot2YiRRHi5RxE7xnxhjQqd6FUk=" rel="nofollow" target="_blank">https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering</a> &#x2A;&#x2A; Photography by Mark Thiessen, NGM Staff, Image Copyright: National Geographic Magazine Please <a href="https://www.globenewswire.com/Tracker?data=7-kvJExrdisegrDjzi5ZDcMqhYy5VYFUiXWSM6esblCR9ulNo2cRJ4CrsVx8FD7XVusykJvsVj1P2RMnbkVSZC3YgAHz8I15A5zJpGZV3DhnzuS0OH71v5pnGFo9ox5Gao7pI2HUOzSGsryEzSLh0g==" rel="nofollow" target="_blank">click here</a> to read the full Kraig Labs analyst report on 247marketnews.com. For more information, please visit: <a href="https://www.globenewswire.com/Tracker?data=vrIGzPBj63iB79eEfjddzErgvNsLq3qhMUolH3c1eSCGSIm_33N7-O8-Qt-hHZqodQXfjeJEymSfw5C6ImsJYRPjc-vS_SZhtdp9vU_zhXI=" rel="nofollow" target="_blank">www.kraiglabs.com</a> Rackspace and Palantir Joint Announcement Springs Momentum Enterprise AI continues shifting from experimentation to operational deployment. Rackspace Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/RXT">RXT</a>) and Palantir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PLTR">PLTR</a>) recently announced a strategic partnership to deploy Palantir's Foundry and Artificial Intelligence Platform (AIP) in production environments under Rackspace's governed managed operations model. The collaboration focuses on accelerating time-to-value for enterprises—particularly in regulated industries requiring strict data sovereignty and compliance. Rackspace will provide implementation, data migration, hosting, and managed services, while scaling its Palantir-trained engineering bench from 30 to more than 250 over the next 12 months. Rackspace brings 25 years of hybrid infrastructure experience, while Palantir contributes its decision-intelligence operating systems. The strategic importance lies in moving AI from demo environments into real-world, mission-critical production use cases. As AI spending transitions from pilot budgets to operational line items, companies that can enable secure, scalable deployment may be positioned for sustained enterprise demand. Ensysce Biosciences: Strategic Review as a Catalyst Layer Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ENSC">ENSC</a>) initiated a formal review of strategic alternatives aimed at enhancing shareholder value and advancing its TAAP&#x2122; and MPAR&#xAE; platforms. The review includes potential partnerships, licensing transactions, capital formation strategies, asset sales, or broader corporate combinations. While no timeline has been set, strategic reviews often introduce optionality into a stock's narrative, particularly for clinical-stage companies with differentiated platforms. Management emphasized disciplined execution while exploring ways to unlock value tied to its proprietary abuse-deterrent and overdose-protection technologies. In biotech, optionality itself can serve as a catalyst if meaningful partnerships or capital events materialize. Contact <a href="https://www.globenewswire.com/Tracker?data=EXHJ897LvpQ2qGxxHm8aL2kRbk0qM8c9Y87SBW4mrCixvRT-8Vo69DGXRU2e2mWk36-wYZHLNH4aWlPNoZBbHa1j6nCnVsfVW2pymwZOfNq-LNgQt0UShbw_lwI5eMEy" rel="nofollow" target="_blank">sales@247marketnews.com</a> for Analyst Report coverage and other investor/public relations services. In today&#39;s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company's profile quickly and effectively. Whether you&#39;re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact <a href="https://www.globenewswire.com/Tracker?data=EXHJ897LvpQ2qGxxHm8aL2kRbk0qM8c9Y87SBW4mrCiFDqcLc5baGUCfFNWGCA70MAC3KmGOxHAP7llEEHvFUOV7cXeId_dX_tkF923Jl96vgEhR0Hq5jC_jfWFTdxv6" rel="nofollow" target="_blank">sales@247marketnews.com</a> to discuss how 24/7 can help accelerate your company's visibility and valuation trajectory. PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor's discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. For further information, please visit <a href="https://www.globenewswire.com/Tracker?data=taXBuR4XE41fUpjZdQVjr0EOU9uUFg4CBP2cfW10r3CJUV-sHfha664L9c96z76aUIiKzF9XdEAzAHmc7TdI_ik1pOOitnsAwJkHpDoQgzo=" rel="nofollow" target="_blank">247marketnews.com</a> or <a href="https://www.globenewswire.com/Tracker?data=718RndY2rvQqs0n1oq4UqRjvICIdp2rjBvrpgz35nrXYtUgIWqRfBx-X7dolkRNG75bryoYK6HkDg6zHtqMN7oP8iCyVWjpijNW6ZfVBckEvuMmpFsOI_-Q90fbatbb_2WrAesTIC4oMQTOu1XTo87UYObV2i9sXw1AY8RuZ_ns=" rel="nofollow" target="_blank">https://go.247marketnews.com/kblb-disclosure/</a> CONTACT: 24/7 Market News <a href="https://www.globenewswire.com/Tracker?data=RFCFdGXsxOvkeDpmiTyjJ4xFPotexYhIU3dR-CCpxlg8WR5P87a1rHWD6Yhaxfmy8L6enWiRM5spM1s61arSqifQ3c7NHfrP7erJatekhKK_8Rj0nHG9Fw4oHYVHC14S" rel="nofollow" target="_blank">Editor@247marketnews.com</a> Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company&#39;s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words &#34;intends,&#34; &#34;may,&#34; &#34;will,&#34; &#34;plans,&#34; &#34;expects,&#34; &#34;anticipates,&#34; &#34;projects,&#34; &#34;predicts,&#34; &#34;estimates,&#34; &#34;aims,&#34; &#34;believes,&#34; &#34;hopes,&#34; &#34;potential&#34; or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company&#39;s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company&#39;s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law. A photo accompanying this announcement is available at <a href="https://www.globenewswire.com/Tracker?data=718RndY2rvQqs0n1oq4UqdS3g0ZaK_Dw6RVnp8ZYkN0fIohFYN8AaSovBqF5UPzo_rnLpUhuelTqcVjK5-ExfpykGowT8484cN1-9g1Jf0EfcHl7ZJ7tOlsPu6J2eMisRX0M_2xASCh8XRrz9Mqa84kN-8sK6kr6XuyhZUuXHkp15c0rm2LvhRvNYD1m18ZLIVNmxPQvqHaH54L1waSdQpLdlRsuSP5RNYWasHvzXorINGv1nueRK1vIxIPo-t0dF-nWjpVKSnp2XbtbM8PZaQ==" rel="nofollow" target="_blank">https://www.globenewswire.com/NewsRoom/AttachmentNg/9733713a-33c0-43ba-82dc-adc50e9aa189</a> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY2Mjg5MSM3NDU5MzE3IzIzMDQzNjM="></img> <img alt="" src="https://ml.globenewswire.com/media/Nzk4YWYyMzctM2YyNS00YmI3LTgzNDItYjVkZTM2ZWU0OTY1LTEzMTU5MTMtMjAyNi0wMi0yNy1lbg==/tiny/24-7-Market-News.png" referrerpolicy="no-referrer-when-downgrade"></img>

Ensysce Biosciences has launched a strategic review aimed at enhancing shareholder value through various potential avenues, including partnerships and licensing. This move could catalyze investment interest and boost stock performance, particularly for its innovative platforms.

Follow-Through Leaders: Production Ramps, AI Alliances, Balance Sheet Strength

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News